Our Programs


We are leveraging our deep understanding of the emerging biology underlying endocrinology and hormone regulation to build a strong clinical pipeline. Our focus is on advancing the development of novel, potentially first-in-class, orally available treatments for endocrine diseases caused by hormone dysregulation where few or no approved medications exist. ATR-101 is an acyl-CoA: cholesterol acyltransferase 1 (ACAT1) inhibitor being investigated in three orphan adrenal indications.